Recent clinical trials for pediatric intermediate and high-risk Hodgkin lymphoma
| Study . | N . | Risk group . | Rx . | Radiation (Gy) . | Directly Assigned to Radiation, % . | EFS, % (y) . |
|---|---|---|---|---|---|---|
| Children’s Oncology Group | ||||||
| CCG59424 | Intermediate: 394 | Intermediate: IA, IB, IIA with adverse features; IIB, III | Intermediate: COPP/ABV ×6 | CR after cycle 6: randomized to 21, IF | 23% of overall study population (not restricted to low risk) | Intermediate: |
| High: 141 | High: IV | High: COPP/ABV, CHOP, etoposide/cytarabine ×2 | vs none; PR: 21, IF | RT: 87; 95 No RT: 83; 100 High: RT: 90; 100 No RT: 81; 94 (10) | ||
| POG942511 | Intermediate: 53 | Intermediate: IB, IIA bulk, IIIA bulk | DBVE-PC ×3-5 (based on response after cycle 3) | 25.5, IF | 100% | Intermediate: 84%; OS NR |
| High: 163 | High: IIB, IIIB, IV | High: 85; OS NR (5) | ||||
| CCG5970412 | 98 | IIB/IIIB with bulk, IV | BEACOPP ×4, RER F: COPP/ABV ×4 RER M: ABVD ×2 SER: BEACOPP ×4 | RER F: None RER M 21, IF SER: 21, IF | 61% | 94; 97 (5) |
| AHOD003127 | 1734 | IB, IA/IIA with bulk, IIB, IIIA, IVA | ABVE-PC ×4, | RER, CR: None | 53% | Overall: |
| SER: ±DECA ×2 | RER, <CR: 21, IF SER: 21, IF | 85; 97.8 RER: 86.9; 98.5 SER: 77.4; 95.3 (4) | ||||
| German Society of Pediatric Oncology | ||||||
| GPOH7 | Intermediate: 139 | Intermediate: IEA/B, IIEA, IIB, IIIA | OPPA (female); OEPA (male) ×2 | 19.8-35 IF | 100% | Intermediate: 88.3; 99.5 |
| High: 239 | High: IIEB, IIIEA/B, IIIB, IV | Intermediate: COPDAC ×2 | High: 86.9; 94.9 | |||
| High: COPDAC ×4 | (5) |
| Study . | N . | Risk group . | Rx . | Radiation (Gy) . | Directly Assigned to Radiation, % . | EFS, % (y) . |
|---|---|---|---|---|---|---|
| Children’s Oncology Group | ||||||
| CCG59424 | Intermediate: 394 | Intermediate: IA, IB, IIA with adverse features; IIB, III | Intermediate: COPP/ABV ×6 | CR after cycle 6: randomized to 21, IF | 23% of overall study population (not restricted to low risk) | Intermediate: |
| High: 141 | High: IV | High: COPP/ABV, CHOP, etoposide/cytarabine ×2 | vs none; PR: 21, IF | RT: 87; 95 No RT: 83; 100 High: RT: 90; 100 No RT: 81; 94 (10) | ||
| POG942511 | Intermediate: 53 | Intermediate: IB, IIA bulk, IIIA bulk | DBVE-PC ×3-5 (based on response after cycle 3) | 25.5, IF | 100% | Intermediate: 84%; OS NR |
| High: 163 | High: IIB, IIIB, IV | High: 85; OS NR (5) | ||||
| CCG5970412 | 98 | IIB/IIIB with bulk, IV | BEACOPP ×4, RER F: COPP/ABV ×4 RER M: ABVD ×2 SER: BEACOPP ×4 | RER F: None RER M 21, IF SER: 21, IF | 61% | 94; 97 (5) |
| AHOD003127 | 1734 | IB, IA/IIA with bulk, IIB, IIIA, IVA | ABVE-PC ×4, | RER, CR: None | 53% | Overall: |
| SER: ±DECA ×2 | RER, <CR: 21, IF SER: 21, IF | 85; 97.8 RER: 86.9; 98.5 SER: 77.4; 95.3 (4) | ||||
| German Society of Pediatric Oncology | ||||||
| GPOH7 | Intermediate: 139 | Intermediate: IEA/B, IIEA, IIB, IIIA | OPPA (female); OEPA (male) ×2 | 19.8-35 IF | 100% | Intermediate: 88.3; 99.5 |
| High: 239 | High: IIEB, IIIEA/B, IIIB, IV | Intermediate: COPDAC ×2 | High: 86.9; 94.9 | |||
| High: COPDAC ×4 | (5) |
Abbreviations are explained in Table 1.